Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00087659 · ClinicalTrials.gov registry record · NA
A Prostate Cancer Study in Men Undergoing Androgen Deprivation Therapy
A NA study, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- NA
- Development phase
NCT00087659: Completed NA study, sponsored by Novartis Pharmaceuticals.
NCT00087659 is a NA study that has completed, run by Novartis Pharmaceuticals. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00087659, a NA study, has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- NA
- Development phase
Study Summary
This study is being conducted to compare the effect of an investigational drug versus placebo on bone loss in men with prostate cancer who are receiving Androgen Deprivation Therapy (ADT). The study drug or placebo will be administered every three months of four treatments in one year. In order to participate, male patients 18 years and older must be consecutive veterans from participating Veterans Administration Medical Centers.
Interventions
- DRUG zoledronic acid
Trial Details
| Field | Value |
|---|---|
| Start Date | 2003-12 |
| Est. Completion | 2007-05 |
| Phase | NA |
What the finished NCT00087659 record still lists
NCT00087659 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.
The record links to 0 conditions, and to 1 intervention - of which zoledronic acid is the first listed.
NCT00087659 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00087659 about?
NCT00087659 is a clinical study titled "A Prostate Cancer Study in Men Undergoing Androgen Deprivation Therapy". This study is being conducted to compare the effect of an investigational drug versus placebo on bone loss in men with prostate cancer who are receiving Androgen Deprivation Therapy (ADT). The study drug or placebo will be administered every three months of four treatments in one year. In order to ...
What is the current status of trial NCT00087659?
This trial is currently completed. It is a NA study. The study started on 2003-12. Estimated completion is 2007-05.
What interventions are being tested in trial NCT00087659?
The interventions under investigation include: zoledronic acid (DRUG).
Who is sponsoring clinical trial NCT00087659?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia